Background: Hypertension, homocysteine and renal resistive index are associated with atherosclerosis and lead to cardiovascular diseases. In this study, we aimed to investigate the association between homocysteine and renal resistive index in patients with newly diagnosed hypertension.
Methods: A total of 221 subjects were included in this case-control study. The study group consisted of 116 hypertensive patients and the control group consisted of 105 healthy subjects. Renal resistive index, homocysteine levels, insulin concentrations and blood pressures were measured.
Results: Renal resistive index, serum homocysteine levels and insulin concentrations were higher in hypertensive patients (p = 0.006, p < 0.001, respectively). Serum homocysteine levels were associated with hypertension (OR 9.5, Cl 95 % 4.86-18.7, p < 0.001). Homocysteine and insulin levels were positively correlated with renal resistive index (r = 0.372, p = 0.001; r = 0.392, p < 0.001, respectively).
Conclusion: High renal resistive index in hypertensive patients is associated with homocysteine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10157-014-1050-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting transforming growth factor-β1 by methylseleninic acid/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential.
Cancer Treat Res Commun
January 2025
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Electronic address:
Clear cell renal cell carcinoma (ccRCC) poses a significant global health challenge as its incidence continues to rise, resulting in a substantial annual mortality rate. Major clinical challenges to current ccRCC treatments include high drug-resistance rates as well as dose-limiting adverse events; underlining the need to identify additional 'druggable' targets. TGF-β1, VEGF, and PD-L1 are potential therapeutic targets in ccRCC.
View Article and Find Full Text PDFUltrasound renal denervation in hypertensive patients: A systematic review and meta-analysis.
PLoS One
January 2025
Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Introduction: Hypertension is the leading noncommunicable disease case affecting 1.28 billion individuals worldwide, with most cases located in low- and middle-income countries. While there are numerous techniques for treating mild to moderate hypertension, properly controlling severe or resistant hypertension poses substantial challenges.
View Article and Find Full Text PDFThe comparison of serum bone-turnover markers in different stage of chronic kidney disease and the associated impact of intradialytic cycling in patients with end-stage renal disease.
Aging (Albany NY)
January 2025
Department of Medicine, Division of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.
Introduction: Bone turnover markers reflected the bone remodeling process and bone health in clinical studies. Studies on variation of bone remodeling markers in different stage CKD were scant, and this study investigated the role of bedside intradialytic cycling in altering concentrations of bone-remodeling markers in patients with end-stage renal disease (ESRD).
Materials And Methods: Participants were segmented into four groups: a group with eGFR >60 ml/min/1.
Reduction of vancomycin-associated acute kidney injury with montelukast.
J Infect Dis
January 2025
Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy; Houston, Texas, 77204, United States of America.
Background: Vancomycin ranks amongst the most utilized antimicrobial agents in the treatment of serious β-lactam-resistant Gram-positive infections, but its use has been associated with nephrotoxicity. Reduction of acute kidney injury (AKI) has been reported in pre-clinical models with adjuvant montelukast. The purpose of the study was to ascertain if montelukast was associated with a reduction in the prevalence of vancomycin-associated AKI.
View Article and Find Full Text PDFRituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome.
Clin Kidney J
January 2025
Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.
Background: Idiopathic nephrotic syndrome (INS) in children, commonly treated with steroids, poses challenges due to associated side effects. Rituximab, known for its efficacy in reducing relapse frequency in difficult-to-treat cases, emerges a potential first-line therapy for pediatric new-onset INS.
Method: This is a single-center, retrospective, observational study to evaluate the efficacy and safety of rituximab as a first-line therapy for pediatric INS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!